BioAge Labs’ Post

Register for our June 25th event in Cambridge, MA to hear more about options for optimizing your biotherapeutic characterization for a spectrum of modalities including mAb's, ADCs, bi-specifics, peptides, oligo's, mRNA's and LNP's. We have something for everyone, so register to discover more! 1 min read

👉 Come and meet ERBC (European Research Biology Center) Group team at booth 38a, supported by #ChooseFrance at the 10th edition of the Nordic Life Science Days (#NLSDays2023), that will be held in Copenhagen, Denmark, on November 29-30, 2023. Learn about our unique AVI-PDX platform, based on the generation of patient tumor replicas in #avian embryos, combined with state-of-the-art 3D microscopy and large-scale molecular analysis for rapid efficacy assessment and in-depth mechanism of action characterization to evaluate #oncology therapeutic candidates. Explore the key benefits of our uniquely innovative technology, which is rapid, representative of patient tumors, predictive of patient response, ethical, robust, and reproducible. These applications cover a wide range of studies, from therapies efficacy evaluation to combination therapy design, mechanism of action studies, and biomarker discovery. Do not hesitate to contact us if you want to arrange a meeting. With the support of MabDesign, the Région Auvergne-Rhône-Alpes, and Lyonbiopôle. #NLSDays #partnering #lifescience #preclinical #CRO #drugdevelopment #animalwelfare #testing #efficacy #research #PDXmodel #invivomodels 

I am participating LSN Webinar to share my two cents on growing interest of JP startups/biotechs on Go-to-market strategy abroad and what improvement is needed to achieve it.

🧬𝐁𝐈𝐎𝐓𝐄𝐂𝐇 𝐒𝐓𝐀𝐑𝐓𝐄𝐑 𝐊𝐈𝐓 – 𝐈𝐍𝐓𝐄𝐋𝐋𝐄𝐂𝐓𝐔𝐀𝐋 𝐏𝐑𝐎𝐏𝐄𝐑𝐓𝐘 𝐑𝐈𝐆𝐇𝐓𝐒 Today Francesca D. is presenting the sixth Biotech Starter Kit’s factsheet we published this Monday. ➡️ Download our sixth factsheet at: https://lnkd.in/eFkAxX5h and watch the video below ↓

Let the second Swiss Biotech Day begin! If you are at the conference and want to have a chat, let’s connect!

The first day of the 9th RSC-BMCS Fragment-based Drug Discovery Conference started with a lively discussion at the 'Meet the Experts' session. Featuring David Rees, Anna Hirsch, and Dan Erlanson. #Fragments24

What a year! Perspectives has explored a myriad of topics this year — from adaptive trial design to advice on regulatory submission to clinical data best practices, and so much more — all written by our many expert authors. ✨ As we approach the end of the year, here is a list of our most-read articles of 2023: https://bit.ly/47blq2X 👏 A big thank you to all of the authors represented in these posts: Ari Brettman (Blackstone Life Sciences), Louis Dron, Scott Gaines, Miguel Hernán (Harvard University), Åsa Holmgren, Vinusha Kalatharan, Florence Le Maulf, Emma Mackay, James Matcham, Cyrus Mehta, Evie Merinopoulou, Natalia Muehlemann, Iffat Rahman, Grammati Sarri, Jason Simeone, Angelo Tinazzi, and Pantelis Vlachos! 👏 #pharma #pharmaceuticalindustry #biotech #realworldevidence #RWE #realworlddata #RWD #FDA #clinicaltrials #clinicaldevelopment #regulatoryaffairs #FDA #oncology #Bayesian #adaptivetrials #software #technology #CDISC #data

Overcoming preclinical hurdles is a big topic in the oncology drug development space. Bispecific antibodies (BsAbs) is a promising frontier in targeted cancer therapies, yet the journey from concept to clinic is fraught with many challenges. Unfortunately, only about 10-15% of BsAB drugs successfully make it to the clinic. A significant portion of these failures can be attributed to the inadequacies of preclinical models that fail to predict clinical outcomes accurately. Selecting appropriate preclinical models is paramount because they provide essential insights into the drug's efficacy and safety profile. In this white paper, we discuss the rising importance of BsAbs as anti-cancer drugs, while emphasizing the importance of implementing an integrated suite of preclinical solutions to accelerate the development of BsAb candidates. A case study of HanX’s BsAb, HX009, is presented to highlight the integrated selection of in vitro and in vivo preclinical solutions used to comprehensively characterize this innovative BsAb. Importantly, these studies were instrumental in supporting the clearance of the company’s IND application submitted to the FDA. At Crown Bioscience, we understand these challenges all too well. By leveraging our integrated solutions approach, combining cutting-edge technology with deep expertise, researchers can enhance the predictability of their preclinical trials, reducing the risk of late-stage failures and accelerating the development of life-saving therapies. #oncology #BsAbs #BispecificAntibodies #DrugDevelopment #PreclinicalModels  https://lnkd.in/dzZg36zA

Explore the future of drug development with Eric Novik, CEO of Generable, at the HITLAB Fall Innovator's Summit! Join his session on 'Challenges and Opportunities in Clinical-Stage Drug Development in the Age of Precision Medicine.'